Cellivery Therapeutics Inc
KOSDAQ:268600
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Uzabase Inc
TSE:3966
|
JP |
|
S
|
Shanghai Holystar Electrical Technology Co Ltd
SSE:688330
|
CN |
Cellivery Therapeutics Inc
Research & Development
Cellivery Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Research & Development
-₩2.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Research & Development
-₩37.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Research & Development
-₩2.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Research & Development
-₩15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-23%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Research & Development
-₩20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Research & Development
-₩171.1B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-36%
|
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
What is Cellivery Therapeutics Inc's Research & Development?
Research & Development
-2.1B
KRW
Based on the financial report for Sep 30, 2024, Cellivery Therapeutics Inc's Research & Development amounts to -2.1B KRW.
What is Cellivery Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
6%
The average annual Research & Development growth rates for Cellivery Therapeutics Inc have been 32% over the past three years , 6% over the past five years .
